Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical director Emiko Higashi filed an initial ownership report showing equity and award holdings in the company. The filing lists 7,600 American Depositary Shares and 17,800 Ordinary Shares held directly, plus restricted stock units and tax-related awards tied to future vesting.
Footnotes explain that 12,800 restricted stock units each convert into one Ordinary Share, then into American Depositary Shares, vesting on June 1, 2026, 2027, 2028 and upon conclusion of board service. Separate Tax Obligation Awards are each economically equivalent to one Ordinary Share and will be settled in cash at vest primarily to cover tax obligations.
TAKEDA PHARMACEUTICAL CO LTD executive Asuka Miyabashira, President of the Japan Pharma Business Unit, reports direct ownership of 3,000 Ordinary Shares. The position also includes 1,600 restricted stock units (RSUs), which are rights to receive one Ordinary Share each as they vest.
The RSUs vest in tranches of 700 shares on June 1, 2026, 500 shares on June 1, 2027, and 400 shares on June 1, 2028. In addition, Miyabashira holds Tax Obligation Awards that are economically equivalent to Ordinary Shares and are designed to be settled in cash primarily to cover tax obligations at the then-current market price when they vest.
Takeda Pharmaceutical Co. Ltd. executive Gabriele Ricci, Chief Data & Tech. Officer, reports beneficial ownership of 124,132 American Depositary Shares. This includes 45,774 restricted stock units, each representing a contingent right to one ADS, vesting on July 1, 2026 (21,952), July 1, 2027 (16,012) and July 1, 2028 (7,810).
Takeda Pharmaceutical Co. Ltd. director Kimberly A. Reed filed an initial beneficial ownership report showing a mix of share holdings and equity awards. She reports direct holdings of 9,700 Ordinary Shares and 8,975 American Depositary Shares. The filing also lists several Tax Obligation Awards, each economically equivalent to one Ordinary Share, covering 1,152, 1,192 and 1,180 underlying Ordinary Shares with vesting and expiration dates on June 1 of 2026, 2027 and 2028. Footnotes explain that separate restricted stock unit awards will vest in tranches of 3,100, 3,400 and 3,200 Ordinary Shares on those same dates, with each RSU converting into one Ordinary Share and then into an equivalent number of American Depositary Shares following vest.
Takeda Pharmaceutical executive Rhonda Janice Pacheco, President of the U.S. Business Unit, filed an initial statement of ownership showing holdings of 149,252 American Depositary Shares. This amount represents an award of restricted stock units, each convertible into one ADS, subject to a multi-year vesting schedule.
The RSUs vest in three equal time-based tranches: 49,750 shares on July 1, 2026, 49,750 shares on July 1, 2027, and 49,752 shares on July 1, 2028. All shares are reported as directly owned, reflecting a significant equity-based compensation grant that aligns the executive’s interests with long-term company performance.
Takeda Pharmaceutical Co Ltd director Michel Bruno Orsinger has filed an initial ownership report detailing his equity interests in the company. The filing lists direct holdings of 7,600 American Depositary Shares and 9,700 Ordinary Shares. It also shows several equity-based awards, including Tax Obligation Awards economically equivalent to 1,152, 1,192 and 1,180 Ordinary Shares, scheduled to vest on different future dates. A cash-settled retirement award is tied to 6,532 Ordinary Shares. Footnotes describe additional restricted stock unit grants that convert into Ordinary Shares or cash upon vesting, with specified vesting dates and retirement-based vesting conditions.
Takeda Pharmaceutical Global Quality Officer Shannon Elaine Mary reported beneficial ownership of 57,580 American Depositary Shares. This filing is an initial ownership report, not a new buy or sell transaction.
The holding includes 27,146 restricted stock units, each equal to one ADS, vesting in tranches on July 1, 2026 (13,144 shares), July 1, 2027 (8,796 shares) and July 1, 2028 (5,206 shares).
Takeda Pharmaceutical director Jean Luc Butel filed an initial ownership report showing his current equity-related interests in the company. He holds 7,600 American Depositary Shares and 9,700 Ordinary Shares directly. The filing also lists several incentive awards tied to Takeda’s stock.
These include Tax Obligation Awards economically equivalent to 1,152, 1,192, and 1,180 Ordinary Shares, each with a 0 exercise price and expirations in 2026, 2027, and 2028, which will be settled in cash mainly to cover tax obligations. A Cash Settled Retirement Award references 6,532 Ordinary Shares and pays cash equal to share value when the director retires. Footnotes describe additional restricted stock units that convert into Ordinary Shares and then ADS upon vesting on June 1, 2026, 2027, and 2028.
TAKEDA PHARMACEUTICAL CO LTD director Miki Tsusaka has reported initial equity interests in the company. The filing shows direct ownership of 6,400 Ordinary Shares. It also lists restricted stock units that vest in tranches of 2,100 shares on June 1, 2026, 2,200 shares on June 1, 2027 and 2,100 shares on June 1, 2028. In addition, the report includes Tax Obligation Awards that are each economically equivalent to one Ordinary Share and are designed to be settled in cash at future vesting dates primarily to cover tax obligations.
Takeda Pharmaceutical’s Chief Financial Officer Furuta Milano has filed an initial ownership report showing existing equity interests. The filing lists direct ownership of 50,100 Ordinary Shares, including 19,500 restricted stock units (RSUs).
The RSUs represent a contingent right to receive one Ordinary Share each, vesting on June 1, 2026 (8,400 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). The report also shows several Tax Obligation Awards, each economically equivalent to one Ordinary Share, that upon vest will be settled in cash primarily to cover tax obligations at the then-current market price, rather than delivering shares. These entries reflect reported holdings rather than open‑market buying or selling.